ERBB2 and breast carcinoma: Among Medicare beneficiaries diagnosed with ERBB2 (formerly HER2 or HER2/neu)–positive breast cancer between 2010 and 2019, are racial and ethnic disparities associated with receipt of ERBB2-targeted therapies, and do these trends change over time?